# Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

> **NCT00706654** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 937 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole depot 300 or 400 mg
- **DRUG:** Aripiprazole 10-30 mg orally
- **DRUG:** Aripiprazole depot 25 or 50 mg
- **DRUG:** Placebo depot
- **DRUG:** Placebo tablets

## Key facts

- **NCT ID:** NCT00706654
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 937 (ACTUAL)
- **Last updated:** 2013-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706654, "Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00706654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*